Abbott baby formula plant under investigation by DoJ after dire shortages
The US Justice Department is investigating the Abbott Laboratories infant formula plant in Michigan that was shut down for months last year due to contamination, the company confirmed
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
The US Justice Department is investigating the Abbott Laboratories infant formula plant in Michigan that was shut down for months last year due to contamination, the company confirmed.
The factory’s closure in February 2022 was a key cause of a nationwide baby formula shortage that forced parents to seek formula from food banks, friends and doctor’s offices. Production restarted in June.
The Justice Department has informed Abbott of its investigation and the company is “cooperating fully,” Abbott spokesperson Scott Stoffel said via email. He declined to provide further details.
The investigation was first reported by The Wall Street Journal, which said the Justice Department's consumer protection branch is looking into conduct at the Sturgis, Michigan, plant that led to its shutdown.
Abbott closed the factory after the Food and Drug Administration began investigating four bacterial infections among infants who consumed powdered formula from the plant. Inspectors uncovered several violations at the plant, including bacterial contamination, a leaky roof and lax safety protocols. But Abbott has stated that its products have not been directly linked to the infections, which involved different bacterial strains.
Abbott is one of just four companies that produce 90 per cent of US formula, and its February recall of several leading brands, including Similac, squeezed supplies that had already been strained by supply chain disruptions and stockpiling during COVID-19 shutdowns.
The shortage was especially acute for children with allergies, digestive problems and metabolic disorders who rely on specialty formulas. The Abbott factory is the only source of many of those products.
The FDA has faced intense criticism for taking months to close the plant and then negotiate its reopening.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.